Related Experiment Videos
[Pulmonary alveolar proteinosis]
Alina Floarea-Strat1, Adriana Stanciu, Mihai Creţeanu
1Laboratorul de Anatomie Patologică, Spitalul Clinic de Boli Infecţioase Sf. Parascheva Iaşi.
Summary
Pulmonary alveolar proteinosis (PAP) is a lung disease with unknown causes, often linked to alveolar macrophage dysfunction. Current treatments like lung lavage are supportive, as specific therapies are lacking.
Area of Science:
- Pulmonary Medicine
- Cell Biology
- Immunology
Context:
- Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by lipid-rich material accumulation in alveoli.
- It presents in congenital and acquired forms, with the acquired type further classified as idiopathic or secondary to specific exposures.
- Common symptoms include dyspnea and cough, with other variable symptoms reported.
Purpose:
- To elucidate the pathogenesis of Pulmonary Alveolar Proteinosis (PAP).
- To explore the role of alveolar macrophages and granulocyte-macrophage colony-stimulating factor (GM-CSF) in PAP development.
- To review current therapeutic approaches for PAP.
Summary:
- PAP involves lipid accumulation in lung alveoli, with pathogenesis suspected to involve alveolar macrophage dysfunction.
- Studies in GM-CSF deficient mice show PAP development, and neutralizing antibodies against GM-CSF are found in idiopathic PAP patients.
- No specific cure exists; whole lung lavage remains the standard treatment for PAP.
Impact:
- Highlights the potential role of GM-CSF in PAP pathogenesis, suggesting future therapeutic targets.
- Underscores the need for novel treatment strategies beyond current supportive care for PAP patients.
- Improves understanding of a rare lung disease, aiding in diagnosis and management.